Have a feature idea you'd love to see implemented?
Let us know!
PSTX Poseida Therapeutics Inc
Price (delayed)
$2.42
Market cap
$235.03M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$1.18
Enterprise value
$288.14M
Poseida Therapeutics is a clinical-stage biopharmaceutical company dedicated to utilizing its proprietary genetic engineering platform technologies to create next generation cell and gene therapeutics with the capacity to cure. Poseida
Highlights
Poseida Therapeutics's debt has decreased by 3.9% YoY
The gross profit has contracted by 44% YoY but it has grown by 7% from the previous quarter
The revenue has contracted by 44% YoY but it has grown by 7% from the previous quarter
Poseida Therapeutics's equity has shrunk by 55% YoY and by 28% QoQ
The quick ratio has declined by 46% year-on-year and by 2% since the previous quarter
Key stats
What are the main financial stats of PSTX
Market
Valuations
Earnings
Shares outstanding
97.12M
Market cap
$235.03M
Enterprise value
$288.14M
Price to earnings (P/E)
N/A
Price to book (P/B)
3.86
Price to sales (P/S)
2.65
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
3.26
Revenue
$88.46M
EBIT
-$103.65M
EBITDA
-$98.04M
Free cash flow
$212,000
Per share
Balance sheet
Liquidity
EPS
-$1.18
Free cash flow per share
$0
Book value per share
$0.63
Revenue per share
$0.91
TBVPS
$3.02
Total assets
$298.69M
Total liabilities
$237.87M
Debt
$83.65M
Equity
$60.82M
Working capital
$151.9M
Debt to equity
1.38
Current ratio
2.48
Quick ratio
2.44
Net debt/EBITDA
-0.54
Margins
Efficiency
Dividend
EBITDA margin
-110.8%
Gross margin
100%
Net margin
-127.5%
Operating margin
-133.9%
Return on assets
-39.7%
Return on equity
-121%
Return on invested capital
-42.9%
Return on capital employed
-52.8%
Return on sales
-117.2%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
PSTX stock price
How has the Poseida Therapeutics stock price performed over time
Intraday
-3.2%
1 week
-4.72%
1 month
-21.43%
1 year
15.24%
YTD
-27.98%
QTD
-15.38%
Financial performance
How have Poseida Therapeutics's revenue and profit performed over time
Revenue
$88.46M
Gross profit
$88.46M
Operating income
-$118.46M
Net income
-$112.77M
Gross margin
100%
Net margin
-127.5%
The gross profit has contracted by 44% YoY but it has grown by 7% from the previous quarter
The revenue has contracted by 44% YoY but it has grown by 7% from the previous quarter
Poseida Therapeutics's net income has decreased by 3.6% from the previous quarter
The operating margin is up by 3.6% since the previous quarter
Growth
What is Poseida Therapeutics's growth rate over time
Valuation
What is Poseida Therapeutics stock price valuation
P/E
N/A
P/B
3.86
P/S
2.65
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
3.26
Poseida Therapeutics's equity has shrunk by 55% YoY and by 28% QoQ
The P/B is 48% more than the 5-year quarterly average of 2.6 and 17% more than the last 4 quarters average of 3.3
The revenue has contracted by 44% YoY but it has grown by 7% from the previous quarter
The stock's price to sales (P/S) is 34% less than its last 4 quarters average of 4.0
Efficiency
How efficient is Poseida Therapeutics business performance
PSTX's ROE is down by 24% since the previous quarter
The ROIC is down by 6% QoQ
PSTX's ROS is up by 3.1% QoQ
PSTX's ROA is down by 2.1% since the previous quarter
Dividends
What is PSTX's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for PSTX.
Financial health
How did Poseida Therapeutics financials performed over time
The total assets is 26% more than the total liabilities
The total liabilities has surged by 63% year-on-year and by 34% since the previous quarter
The quick ratio has declined by 46% year-on-year and by 2% since the previous quarter
Poseida Therapeutics's debt is 38% higher than its equity
Poseida Therapeutics's debt to equity has surged by 116% YoY and by 38% QoQ
Poseida Therapeutics's equity has shrunk by 55% YoY and by 28% QoQ
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.